An Open-label Study With NVC-001 In Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

Overview

About this study

This study will be conducted to evaluate the safety and tolerability, and assess exploratory efficacy of NVC-001 in adults participants with LMNA-Related Dilated Cardiomyopathy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key Inclusion Criteria:

* Able to provide full informed consent and comply with all requirements of the study protocol
* Male or female participants ≥18 years old
* Pathogenic or likely pathogenic mutation of LMNA
* NYHA Class I, II, or III
* Anti-AAV9 neutralizing antibody titer per protocol-specified criteria
* Adequate hepatic and renal function per protocol-specified criteria

Key Exclusion Criteria:

* Any chronic medical condition that in the opinion of the Investigator would compromise the safety and/or compliance of the enrolled participant
* Any clinically relevant change in standard of care heart failure medication prior to the Screening Visit
* Any unstable cardiac symptoms requiring cardiac surgery, myocardial infarction, or percutaneous coronary intervention within 6 months prior to Screening
* NYHA class IV or anticipated need for LVAD or transplant in the next 6 months
* Pregnant or lactating or planning to become pregnant
* Receiving an investigational intervention or participating in another clinical study within 30 days or within 5 half-lives of the drug prior to Screening
* Prior participation in any gene therapy or approved gene therapy clinical study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Giudicessi, M.D., Ph.D.

Contact us for the latest status

Contact information:

CVRU Heart Rhythm Services Research Team

(507) 255-0774

More information

Publications

Publications are currently not available
.
CLS-20601671

Mayo Clinic Footer